This Company Is Doubling Down on AI. Is the Stock a Buy?

Core Insights - Eli Lilly is leveraging artificial intelligence (AI) to enhance drug discovery, partnering with Nvidia to invest up to $1 billion over five years in an innovation lab [2][3] - The company has a strong market position in weight management drugs, with its product tirzepatide becoming the best-selling drug globally, contributing to a 54% year-over-year revenue growth to $17.6 billion in Q3 [6] - Eli Lilly is diversifying its pipeline beyond its core therapeutic areas, with recent approvals in eczema, cancer, and Alzheimer's disease, and aims to launch more products in the next five years [8][9] Investment Potential - The AI initiatives may not yield immediate results, but they position Eli Lilly as a potential leader in transforming drug discovery [5] - The company has demonstrated consistent dividend growth, increasing its dividend by 103.5% over the past five years, making it an attractive option for dividend-seeking investors [10]